To include your compound in the COVID-19 Resource Center, submit it here.

Thalidomide regulatory update

The U.K.'s NICE issued a second final appraisal determination (FAD) recommending the use of Celgene's thalidomide and Velcade bortezomib from Johnson & Johnson

Read the full 234 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE